# Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

> **NCT02641041** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 24 (actual)

## Conditions studied

- Central Nervous System (CNS) Demyelinating Disease
- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BIIB033
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02641041
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641041, "Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02641041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*